[New targets and drugs for treatment of lipid metabolism disorders].
Rau
Oliver
O
Institut für Pharmazeutische Chemie der Johann Wolfgang Goethe-Universität, Frankfurt.
Zettl
Heiko
H
Popescu
Laura
L
Steinhilber
Dieter
D
Schubert-Zsilavecz
Manfred
M
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007408:Intestinal Absorption / Q000187:drug effects; D052439:Lipid Metabolism Disorders / Q000188:drug therapy*; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors
D000924:Anticholesteremic Agents; D000975:Antioxidants; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D047492:Peroxisome Proliferator-Activated Receptors; C106092:microsomal triglyceride transfer protein; D002785:Sterol O-Acyltransferase